Hot Investor Mandate: Investment Platform with Billions of AUM Invests $10-15M in Advanced Therapeutics, Next-Generation Devices, Diagnostics, Tools, and More

17 Mar

An investment platform with around €4B in assets under management spans both venture and private equity. Since its inception, the firm has completed 200+ investments. The firm’s latest fund, a dedicated healthcare and life science fund, targets venture and growth stage Tech-Enabled Medicine companies operating at the convergence of health, life sciences and technology. Investment sizes can range from $5M (Seed to Series A) to $50M (Crossover), with average initial check sizes expected to be around $10-15M, and a significant portion will be reserved for later rounds. The firm’s sweet spot is in Series B to C companies.

The firm invests globally across Asia, North America, and Europe (including Middle East). The firm is particularly interested in companies that want to expand to other geographic markets and assist companies to scale globally.

The firm will invest in six areas at the convergence of health, life sciences and technology:

  1. Life science tools – tools enabling advanced diagnostics / treatment: automated cell manufacturing & supply chain management for cell therapy, single cell manipulation, multi-omics consumables & reagents
  2. Diagnostics – enable more precise diagnostics, early detection, treatment support: clinical multi-omics, companion Dx, digital imaging / pathology with AI, clinical decision support systems
  3. Clinical trial enablement – finding the right patient and supporting distributed trials: patient subpopulation selection, trial site matching, virtual / decentralized trials, continuous trial monitoring, real world evidence
  4. Advanced Therapeutics – new modalities enabled by new technology: AI-driven drug discovery, cell & gene therapy, gene editing, microbiome, protein modulation, etc.
  5. New care models – changing point of care & virtual treatments: telehealth, digital therapeutics, digital mental health, wearables, chronic disease monitoring solutions
  6. Next-gen devices / materials – implantables enabled by novel materials / miniaturization, connected devices: biopolymers, non-invasive treatments, monitoring, closed loop therapies, robotic surgery, 3D printing

The firm likes to see strong management teams with proven track record and problem-solving skills or outstanding scientific founders.

The company should have innovation with impact, a clear development and regulatory approval pathway, and capital efficiency (defined timeline and budget and prudent approach to valuation). The firm can lead and co-invest depending on the investment opportunity, and seeks board representation when acting as the lead investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: